About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker ANGO · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Jun 11, 2026Irreversible Electroporation (IRE) for the Treatment of Lower Urinary Tract Symptoms (LUTS) in Men…
NCT07640776 · Lower Urinary Tract Symptoms (LUTS) in Men With Benign Pros…
Irreversible Electroporation
ANGO
Angiodynamics, Inc.
Not applicableNot yet recruiting40Dec 2027Registry ↗
Jun 2, 2026Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue
NCT04972097 · Prostate Cancer
Irreversible Electroporation
ANGO
Angiodynamics, Inc.
Not applicableCompleted121Aug 14, 2024Registry ↗
May 18, 2026Post-Market Registry of AURYON Atherectomy Device in Subjects Affected With Infrainguinal Periphera…
NCT04229563 · Infrainguinal Peripheral Artery Disease, Peripheral Arteria…
AURYON Atherectomy System
ANGO
Angiodynamics, Inc.
—Completed102Mar 17, 2021Registry ↗
May 11, 2026Acute Pulmonary Embolism Treatment With the AlphaVac Multipurpose Mechanical Aspiration System and…
NCT07280247 · Pulmonary Embolism Acute
AlphaReturn Blood Management System
ANGO
Angiodynamics, Inc.
Not applicableRecruiting39Dec 2026Registry ↗
Apr 22, 2026Percutaneous AngioVac Vegetation Extraction (PAVE) to Remove Right Heart Vegetations in Patients Wi…
NCT07282002 · Infective Endocarditis (IE)
AngioVac System
ANGO
Angiodynamics, Inc.
Not applicableNot yet recruiting30Nov 2026Registry ↗
Mar 16, 2026Auryon Atherectomy System With Standard Balloon Angioplasty Versus Standard Balloon Angioplasty Alo…
NCT07472439 · Peripheral Arterial Disease
Auryon Atherectomy System, Balloon Angioplasty
ANGO
Angiodynamics, Inc.
Not applicableNot yet recruiting50May 2029Registry ↗
Jan 8, 2026Auryon Atherectomy System With Standard Balloon Angioplasty Versus Standard Balloon Angioplasty Alo…
NCT06777901 · Peripheral Arterial Diseases
Auryon Atherectomy System, Balloon Angioplasty
ANGO
Angiodynamics, Inc.
Phase 4Recruiting224Feb 2029Registry ↗
Oct 10, 2025International Study on Treatment of Liver (HCC) Patients With IRE
NCT07192731 · Hepatocellular Carcinoma (HCC), Liver Ablation
Irreversible Electroporation
ANGO
Angiodynamics, Inc.
Not applicableNot yet recruiting50Feb 2028Registry ↗
Oct 10, 2025International Study on Treatment of Patients With Metastatic Colorectal Liver Lesions Patients With…
NCT07191548 · Colorectal Adenocarcinoma Metastatic in the Liver, Liver Ab…
Irreversible Electroporation
ANGO
Angiodynamics, Inc.
Not applicableNot yet recruiting50Feb 2028Registry ↗
Sep 26, 2025Evaluating the Efficacy, Safety and Long Term Functional Outcomes of Percutaneous Mechanical Aspira…
NCT06697314 · Acute Pulmonary Embolism (PE), Pulmonary Embolism
AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 Sys…
ANGO
Angiodynamics, Inc.
Not applicableRecruiting256Jun 2028Registry ↗
Feb 12, 2025A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer
NCT03899649 · Stage III Pancreatic Cancer
SOC, NanoKnife System
ANGO
Angiodynamics, Inc.
—Active, not recruiting532Apr 2025Registry ↗
Feb 12, 2025A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer
NCT03899636 · Stage III Pancreatic Cancer
Modified FOLFIRINOX Regimen, NanoKnife System
ANGO
Angiodynamics, Inc.
Phase 3Active, not recruiting528Apr 2025Registry ↗
Jul 19, 2024Evaluating the Safety and Efficacy of the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 P…
NCT05318092 · Pulmonary Embolism, Acute Pulmonary Embolism
AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE
ANGO
Angiodynamics, Inc.
Not applicableCompleted122Jan 4, 2024Registry ↗
Feb 1, 2023Study of NanoKnife for Ablation of Prostate Cancer in Intermediate Risk Patients
NCT01972867 · Prostate Cancer
NanoKnife Procedure
ANGO
Angiodynamics, Inc.
Not applicableUnknown6Nov 1, 2022Registry ↗
May 19, 2020SeCure Endovenous Laser Treatment Study
NCT02215369 · Chronic Venous Insufficiency
VenaCure EVLT 400 µm fiber Procedure Kit
ANGO
Angiodynamics, Inc.
Not applicableCompleted112Mar 2018Registry ↗
May 17, 2019The PROOF Study: The PICC Related Obstruction Of Flow Study
NCT01921114 · Patients Indicated for a PICC for Any Medical Condition
BioFlo™ Peripherally Inserted Central Catheter (PICC), Bard…
ANGO
Angiodynamics, Inc.
Not applicableTerminated57Jul 2014Registry ↗
Dec 8, 2017Initial Experience With the AngioVac Venous Drainage Cannula
NCT02775565 · Heart Disease
AngioVac
ANGO
Angiodynamics, Inc.
—Completed51Sep 2016Registry ↗
Nov 8, 2016NanoKnife Low Energy Direct Current (LEDC) System in Subjects With Locally Advanced Unresectable Pa…
NCT01369420 · Pancreatic Adenocarcinoma
NanoKnife Low Energy Direct Current (LEDC) System Ablation
ANGO
Angiodynamics, Inc.
Phase 2Completed10Dec 2011Registry ↗
Nov 8, 2016Pilot Study of Irreversible Electroporation (IRE) to Treat Early-Stage Primary Liver Cancer (HCC)
NCT01078415 · Carcinoma, Hepatocellular
Ablation with the NanoKnife Low Energy Direct Current (LEDC…
ANGO
Angiodynamics, Inc.
Not applicableCompleted26Jan 2013Registry ↗
Nov 8, 2016Post-Market Observation Study of Intra-renal Drug Delivery (PROVIDE)
NCT01064895 · Acute Kidney Injury, Acute Renal Failure
Benephit catheter for Targeted Renal Therapy
ANGO
Angiodynamics, Inc.
—Terminated—Dec 2011Registry ↗

20 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 10:47 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances